AU2022242811A1 - Modified peptidomimetics and methods of use - Google Patents

Modified peptidomimetics and methods of use Download PDF

Info

Publication number
AU2022242811A1
AU2022242811A1 AU2022242811A AU2022242811A AU2022242811A1 AU 2022242811 A1 AU2022242811 A1 AU 2022242811A1 AU 2022242811 A AU2022242811 A AU 2022242811A AU 2022242811 A AU2022242811 A AU 2022242811A AU 2022242811 A1 AU2022242811 A1 AU 2022242811A1
Authority
AU
Australia
Prior art keywords
synthetic polypeptide
subject
eld607
infection
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022242811A
Other languages
English (en)
Other versions
AU2022242811A9 (en
Inventor
Saira AHMAD
Maria Florencia SASSANO
Robert Tarran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU2022242811A1 publication Critical patent/AU2022242811A1/en
Publication of AU2022242811A9 publication Critical patent/AU2022242811A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022242811A 2021-03-22 2022-03-22 Modified peptidomimetics and methods of use Pending AU2022242811A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163164132P 2021-03-22 2021-03-22
US63/164,132 2021-03-22
PCT/US2022/021391 WO2022204185A1 (en) 2021-03-22 2022-03-22 Modified peptidomimetics and methods of use

Publications (2)

Publication Number Publication Date
AU2022242811A1 true AU2022242811A1 (en) 2023-09-28
AU2022242811A9 AU2022242811A9 (en) 2024-01-25

Family

ID=83397833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022242811A Pending AU2022242811A1 (en) 2021-03-22 2022-03-22 Modified peptidomimetics and methods of use

Country Status (5)

Country Link
US (1) US20240182523A1 (https=)
EP (1) EP4314010A4 (https=)
JP (1) JP2024511119A (https=)
AU (1) AU2022242811A1 (https=)
WO (1) WO2022204185A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP2655646A4 (en) * 2010-12-20 2014-05-21 Du Pont TARGETED PERHYDROLASES
EP2760463B1 (en) * 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US10894811B2 (en) * 2016-02-22 2021-01-19 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
CN106749679A (zh) * 2017-01-10 2017-05-31 中国人民解放军疾病预防控制所 抗P选择素单链抗体靶向抑制物融合蛋白ScFv‑SPLUNC1及其表达方法与应用

Also Published As

Publication number Publication date
EP4314010A4 (en) 2025-03-05
AU2022242811A9 (en) 2024-01-25
WO2022204185A1 (en) 2022-09-29
EP4314010A1 (en) 2024-02-07
JP2024511119A (ja) 2024-03-12
US20240182523A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
E. Greber et al. Antimicrobial peptides under clinical trials
DK2760463T3 (en) REGULATION OF SODIUM CHANNELS USING PLUNC PROTEINS
JP5784078B2 (ja) 呼吸器疾患の治療方法
WO2012013979A1 (en) Anti-viral agent
US20170080053A1 (en) Regulation of sodium channels by plunc proteins
KR20210024005A (ko) 스태필로코커스 아우레우스 및 그람 양성 세균을 항생제에 재민감화시키기 위한 리신 및 이의 유도체
TW201028154A (en) Antibiotic synergism
JP2026009914A (ja) 免疫治療薬に用いられるペプチド
US20190030114A1 (en) Isoform-specific calpain inhibitors, methods of identification, and uses thereof
AU2022242811A9 (en) Modified peptidomimetics and methods of use
US20250114430A1 (en) Modified peptidomimetics and methods of use
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
JP2025000998A (ja) ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
US20240398910A1 (en) Methods and compositions for the treatment of coronavirus infection, including sars-cov-2
CN112153897B (zh) 用于治疗神经病学和其他病症的组合物和方法
WO2025059165A1 (en) Methods of use for rhamm-derived peptides and rhamm-derived peptide mimetics
EP3419994B1 (en) Peptide inhibitors of calcium channels
CA3046361A1 (en) Saline formulations of splunc1 peptides
US20210322511A1 (en) Methods and compositions for treating a respiratory disease
US20250049913A1 (en) Nucleic acid structure utilizing snare
Forde Novel Host Defence Peptide Prodrugs for use in Cystic Fibrosis
CN110366422A (zh) 包含其中细胞穿透肽与ctctla4肽融合的融合蛋白作为活性成分的用于预防或治疗炎性呼吸系统疾病的药物组合物
US20200102358A1 (en) Methods and compositions related to recombinant neil2
CN115209912A (zh) 肽组合物及其使用方法
Saad et al. Salivary flow, sodium renal excretion, urinary volume and arterial blood pressure induced by pilocarpine: influence of nitric oxide

Legal Events

Date Code Title Description
SREP Specification republished